Biogen News and Research

RSS
Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Caliper Life Sciences presents the benefits of its LabChip GX platform

Caliper Life Sciences presents the benefits of its LabChip GX platform

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Rituxan's sBLA receives a Complete Response from the FDA

Rituxan's sBLA receives a Complete Response from the FDA

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

FBC Acquisition commences tender offer to acquire all outstanding shares of Facet Biotech

H1N1 infected people continue to shed live virus days after the symptoms

H1N1 infected people continue to shed live virus days after the symptoms

Genentech releases Phase III PRIMA study findings

Genentech releases Phase III PRIMA study findings

GENova to sign extensive collaboration agreement with Beckpharma

GENova to sign extensive collaboration agreement with Beckpharma

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Linguistic Systems is MBC's first language translation member

Linguistic Systems is MBC's first language translation member

Genova gains access to Big Pharma's distribution channels

Genova gains access to Big Pharma's distribution channels